HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
1-((5-(p-Chlorophenyl)furfurylidene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)hydantoin dihydrochloride
Azimilide HCl · Azimilide 2HCl · Unii-6E6vjp68kr · Azimilide hydrochloride · NE-10064 Dihydrochloride · AziMilide Dihydrochloride · Azimilide Dihydrochloride, 10 mM in DMSO · Azimilide dihydrochloride (NE-10064 dihydrochloride)
Identifikatoren & physikalische Daten
| CAS No. | 149888-94-8 |
|---|---|
| Summenformel | C23H30Cl3N5O3 |
| Durchschnittliche Molmasse | 530,9 g/mol |
| SMILES | CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1.Cl.Cl |
| InChIKey | HHPSICLSNHCSNZ-UHFFFAOYSA-N |
| PubChem CID | 60938 |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 72,6 |
|---|---|
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 6 |
| Frei drehbare Bindungen | 8 |
| Schwere Atome | 34 |
| Formalladung | 0 |
| Komplexität | 677 |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | DMSO: soluble1mg/mL, clear (warmed) |
| Aggregatzustand | powder |
| Farbe | white to beige |
| InChIKey | SUHOTCCGXXEWJN-DSHYBBOZSA-N |
| SMILES | Cl.Cl.CN1CCN(CCCCN2C(=O)CN(\N=C/c3ccc(o3)-c4cccc(Cl)c4)C2=O)CC1 |
Sicherheit & Vorschriften
| Wassergefährdungsklasse (WGK) | 3 |
|---|---|
| UN-Transportnummer | UN 2811 6.1 / PGIII |
| R-Sätze (R) | 25 |
| Gefahrensymbole | T |
| Sicherheitshinweise (S) | 45 |
| Lagerklasse | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
| Gefahrenklasse | Acute Tox. 3 Oral |
Anwendungen & Verwendung
Verwenden
Azimilide Dihydrochloride is an oral type III potassium channel blocker agent that blocks both the rapid activating component and the slow activating component of the delayed rectifier potassium current. Both preclinical and clinical studies have demonstrated the efficacy of azimilide and its safety in the treatment of supraventricular and ventricular tachyarrhythmia. Azimilide also is being studied in a worldwide multicenter trial for prevention of sudden cardiac death in patients after myocardial infarction.